USFDA advisers to weigh full nod for Eisai-Biogen Alzheimer's drug Leqembi Ruchika Sharma11 April 2023 10:00 AM ISTLeqembi belongs to a class of treatments that aim to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic protein...
Setback: Merck, Eisai to stop late-stage study of Keytruda plus Lenvima for metastatic melanoma Ruchika Sharma8 April 2023 2:01 PM ISTThey also said another late-stage trial for Keytruda and Lenvima did not meet its main goal of overall survival for treating a type of colorectal or...
USFDA grants priority review for Eisai Alzheimer's drug LEQEMBI Ruchika Sharma8 March 2023 10:00 AM ISTTokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics...
Eisai dissolves joint venture with Bracco Imaging Ruchika Sharma21 Feb 2023 2:30 PM ISTItaly: Bracco Imaging S.p.A and Eisai Co., Ltd. have announced that the joint venture regarding the company Bracco-Eisai Co., Ltd., will be dissolved...
Eisai-Biogen Alzheimer's drug Lecanemab should be priced below Aduhelm: Report Ruchika Sharma25 Dec 2022 2:00 PM ISTTreatment with the drug may provide a small or even substantial benefit to patients with early Alzheimer's, but there remains a possibility of net...
Lupin rolls out Seizure drug Rufinamide in US Ruchika Sharma5 Dec 2022 3:15 PM ISTMumbai: Pharma major Lupin Limited today announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg in the United States market.The...
Roche to stop all Gantenerumab studies in early Alzheimer's disease Ruchika Sharma2 Dec 2022 2:30 PM ISTRoche is still testing a different formulation of gantenerumab called trontinemab, designed to ferry the drug across the blood brain barrier -...
Lupin bags USFDA okay for seizure treatment drug Rufinamide Ruchika Sharma18 Aug 2022 3:23 PM ISTRufinamide Tablets will be manufactured at Lupin’s facility in Goa, India.
USFDA decision on Eisai, Biogen Alzheimer's drug due in January Ruchika Sharma6 July 2022 10:00 AM ISTEisai in March downsized its role in Aduhelm, but remains the leader in the 50-50 partnership's lecanemab program.
Eisai gets Japanese orphan drug designation for ultrahigh-dose mecobalamin with prospective indication for functional impairment of amyotrophic lateral sclerosis Ruchika Sharma30 May 2022 11:00 AM ISTALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron...
Merck, Eisai get Japanese nod for cancer cocktail drug Keytruda, Lenvima Ruchika Sharma30 Dec 2021 12:22 PM ISTKenilworth: Merck, known as MSD outside the United States and Canada, and Eisai have announced that the Japanese Ministry of Health, Labour and...
Biogen gets USFDA Fast Track designation for lecanemab Ruchika Sharma26 Dec 2021 9:30 AM ISTTokyo: Eisai Co., Ltd. and Biogen Inc. have announced that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the...
